Brief: Xbrane says expect to enter into agreement for out-licensing of Spherotide to China in Q1 2018

Xbrane Biopharma AB

21/12/2017 22:45

Dec 21 (Reuters) - Xbrane Biopharma Ab  XBRANE.ST : 
    * REG-XBRANE BIOPHARMA INFORMS ABOUT ONGOING NEGOTIATIONS 
CONCERNING OUT-LICENSING OF SPHEROTIDE TO CHINA 
    * XBRANE IS IN DISCUSSIONS AND NEGOTIATIONS WITH POTENTIAL 
PARTNERS REGARDING OUT-LICENSING OF SPHEROTIDE AND XLUCANE 
    * FINAL NEGOTIATION FOR AGREEMENT TOOK PLACE DURING CHINESE 
PARTNER'S VISIT IN SWEDEN AND IN ITALY IN DECEMBER 
    * ENTERING OF AGREEMENT IS EXPECTED TO TAKE PLACE DURING Q1 
OF 
2018 
    * ONE OF THESE NEGOTIATIONS CONCERNS OUT-LICENSING OF RIGHTS 
TO 
SELL, MARKET SPHEROTIDE IN CHINA TO A LARGE CHINESE COMPANY 
 
Source text for Eikon:  ID:nGNEb5zJD  
Further company coverage:  XBRANE.ST  
 
 ((Bangalore.newsroom@thomsonreuters.com;))